Idaho News Updates

• Portfolio of Proprietary Pharmaceutical and Nutraceutical Brands, Including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.

• Manufacturing Pharmaceuticals, Food Supplements, Cosmetics, Biocides and Medical Devices Within the European Union.

• Markets to Retail Pharmacies and Wholesale Distributors Through Subsidiaries in Greece and the UK.

• R&D Partnerships for Major Health Disorders Enhanced by AI Drug Repurposing via Novel Patented Nutraceuticals, Root Extracts, Proprietary Complex Generics and OTC Products.

• Entered the Telehealth Space Through the Acquisition of ZipDoctor, Inc., Based in Texas with a Global Distribution Platform.

• Total Liabilities Decreased by $4.5 Million, or 9.6%, Quarter-Over-Quarter, While Stockholders’ Equity Increased 7.6%.

• R&D Division in Discussions with the European Investment Bank for Financing of up to €25 million.

• 4,874,126 Series B Warrants Expired Unexercised, Eliminating ~38% of Total Warrant Overhang with Zero Shareholder Dilution.

• Wholly Owned Real Estate Facilities Independently Valued at Approximately $15 Million — Exceeding Current Market Capitalization.

• Guidance Projects Stockholders’ Equity of $92.3 Million by 2029, Driven by a Growing Cash Position of $62.9 Million from Internally Generated Cash Flow.

• Entering $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing.

• Revenue Increasing 207% at a 32% CAGR: From $65.3 Million in 2025 to $200.6 Million by 2029, Driven by Strong Growth Across All Core Segments.

• Gross Profit Growing 801% to $71.2M: Margins Expanding From 12.1% to 35.5% Driven by a Structural Shift Toward High-Margin Proprietary Segments.

• Net Income Improving by $50.1M: Transition to Profitability in 2027; Net Income of $31.0 Million by 2029.

• Self-Funding Growth Model: Operating Cash Flow Turning Positive in 2027 at $11.9 Million, More Than Doubling to $24.0 Million by 2029.

• Balance Sheet Transformation: Cash up 18-Fold to $62.9 Million; All Convertible Notes Repaid; Cash Anticipated to Exceed Total Debt Levels by 2027.

• Shareholder Value: Stockholders’ Equity up 402% to $92.3 Million and Per-Share Value Creation with EPS of $0.73 by 2029.

• Clear Growth Drivers: High-Margin Proprietary Products, Distribution and Manufacturing Expansion, Global Partnerships, R&D Advancement, AI-Driven Efficiencies and Disciplined Capital.

Cosmos Health, Inc. (Nasdaq: COSM) $COSM is a diversified, vertically integrated global healthcare group. COSM owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), COSM manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.

COSM also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, COSM has established R&D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products.

COSM has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, COSM is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.

European Investment Bank Financing Discussions for up to €25M, Eliminating 38% of Warrants with No Dilution, Reaffirming Business Growth Trajectory

On June 2nd COSM provided an update on its balance sheet and noted no known business reason for the recent decline in its share price. The COSM balance sheet is trending positively across multiple key metrics, as reported in the Company’s Q1 2026 results:

Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, driven by a substantial reduction in convertible note and credit facility balances

Stockholders’ equity increased by $1.4 million, or 7.6%, quarter-over-quarter

Liabilities-to-assets ratio improved by 370 basis points to 68.2% from 71.9% at year-end 2025

Liquid assets of $4.3 million comprising cash of $2.2 million and digital assets and marketable securities of $2.1 million

Beyond the quarterly metrics, The COSM balance sheet is underpinned by a diversified asset base spanning GMP-certified manufacturing facilities, a robotic logistics warehouse, pharmaceutical distribution infrastructure, proprietary intellectual property, digital assets, and a growing U.S. commercial platform.

COSM is in discussions with the European Investment Bank (EIB) for financing of up to €25 million, reflecting up to 50% of its broader €50 million R&D initiative. If successfully concluded, this financing would represent a significant milestone for the COSM R&D platform, which is anchored by the proprietary AI-driven Cloudscreen drug repurposing technology and spans oncology, autoimmune diseases, neurology, and obesity.

4,874,126 Series B Warrants have expired unexercised, eliminating approximately 38% of total outstanding warrants with no shareholder dilution. This represents a meaningful simplification of the COSM capital structure that directly benefits existing shareholders.

COSM holds Real Estate Assets wholly owned, independently valued at over $15 Million. A large portion of these assets are free of any mortgage or other financial encumbrance. The market value of these assets alone exceed the Company’s current market capitalization and represent a meaningful component of the COSM asset base the Company believes is not yet reflected in its share price.

COSM has secured a financing facility of up to $300 million to support its digital assets treasury strategy. COSM has commenced investments in digital assets, with the strategy providing balance sheet diversification and a platform to explore blockchain’s practical applications in healthcare, while retaining significant capital for core operations.

COSM is growing at its fastest pace in Company history — FY2025 revenue of $65.3 million was an all time annual record, up 20% year-over-year with gross profit growing 83%, followed by Q1 2026 revenue of $17.9 million, the highest in COSM history, up 31% year-over-year, with momentum continuing into Q2 2026 across all core divisions.

COSM 2026-2029 Guidance projects this trajectory to drive a structural transformation of the balance sheet: revenue growing to $200.6 million by 2029 at a 32% CAGR, gross margins expanding from 12.1% to 35.5%, Adjusted EBITDA reaching $44.2 million, operating cash flow of $24 million, a cash position of $62.9 million, and stockholders’ equity growing 402% to $92.3 million — with all convertible debt projected to be fully repaid and cash expected to exceed total debt by 2027.

Entering $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

On June 1st COSM announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company’s first entry into the animal health market.

COSM intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.

The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand View Research.

European Veterinary Standards Testing

COSM C-Scrub Wash 4% successfully demonstrated bactericidal activity according to EN 1656:2019 and yeasticidal activity according to EN 1657:2024 following independent testing conducted by Quality Assurance & Control Systems Ltd. (QACS), an EU-based testing laboratory accredited according to EN ISO/IEC 17025:2017.

For more information on $COSM visit: www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr/en/home/, www.zipdoctor.co, https://cloudscreen.gr/en/

Email: [email protected] or [email protected]

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Cosmos Health, Inc. (Nasdaq: COSM)
Contact Person: BDG Communications
Email: Send Email
Phone: (312) 865-0026
Address:141 West Jackson Blvd., Suite 4234
City: Chicago
State: IL 60604
Country: United States
Website: https://www.cosmoshealthinc.com/